SGS Acquires Keystone Bioanalytical, Strengthening End-to-End Drug Development Lifecycle Testing Capabilities for North American Pharma and Biotech Industries

SGS, a global leader in testing, inspection, and certification, has announced its acquisition of Keystone Bioanalytical, a Philadelphia-based provider of bioanalytical testing services. The deal, finalized on May 4, 2026, comes at an undisclosed value and aims to enhance SGS's bioanalytical testing capabilities within the North American pharmaceutical and biotechnology sectors. This acquisition aligns with SGS's strategic initiative, known as Strategy 27, which seeks to double its North American sales by 2027.

Keystone Bioanalytical, established in 2001, specializes in quantitative liquid chromatography-mass spectrometry (LC-MS/MS) method development, validation, and analysis. The company operates a 10,000 square foot facility that is compliant with Good Laboratory Practice (GLP) standards, delivering bioanalytical services across both pre-clinical and clinical phases of drug development. Keystone has built a reputation for its rapid turnaround times and expertise in complex small molecule and biomarker projects, serving a diverse clientele in the pharmaceutical and biotech industries.

The acquisition of Keystone Bioanalytical is particularly strategic for SGS as it expands the company's GLP-compliant bioanalysis capabilities, responding to the increasing demand for high-quality bioanalytical services driven by stringent regulatory oversight in North America. Regulatory agencies such as the U.S. Food and Drug Administration and Health Canada have heightened expectations for safety and compliance, which further fuels the need for reliable bioanalytical testing. By integrating Keystone's specialized services, SGS positions itself to better meet the evolving needs of its clients in drug development.

SGS has been a key player in the North American pharmaceutical landscape for over three decades, leveraging its extensive experience across the drug development lifecycle. With a global network of over 20 laboratories in 11 countries, including 10 GLP-compliant sites, SGS is well-equipped to support the pharmaceutical and biotechnology sectors worldwide. This acquisition not only enhances SGS's service offerings but also strengthens its competitive position in a rapidly evolving market.

Looking ahead, the acquisition of Keystone Bioanalytical is expected to have broader implications for the pharmaceutical and biotechnology sectors. As companies increasingly seek to innovate and expedite drug development processes, the demand for comprehensive and high-quality bioanalytical testing services is likely to grow. SGS's enhanced capabilities through this acquisition will enable it to better support clients in navigating the complexities of drug development, ultimately contributing to the advancement of innovative therapies and medicines in the market.